Additional TN-C-specific antibodies have been tested in recurrent malignant glioma patients (antibodies BC-2-131I, BC-4-131I; clinical phase II) and in anaplastic astrocytoma and glioblastoma patients (BC4-biotin + avidin + 99Y-biotin; clinical phase I) and revealed disease stabilization with partial remission (185, 186). Here, TNC is linked to glioblastoma.